Angel Bridge

Lisse, established in 2018 and headquartered in Tokyo, Japan, specializes in developing and providing automatic contract review solutions. The company offers a 24-hour contract checking service, LeCHECK, which employs AI to support contract checking and creation. Additionally, Lisse provides LeTRANSLATE, a real-time, high-quality machine translation tool for English contracts. By combining legal expertise with technology, Lisse aims to enhance corporate legal affairs, mitigate transaction risks, and foster a dispute-free society.

SmartRyde is a Tokyo-based company founded in 2017 that specializes in airport transfer services. It operates a reservation platform that connects travelers with a wide variety of transportation options from over 650 operators worldwide. SmartRyde’s platform is designed to facilitate safe and seamless airport transfers, allowing users to pre-book their rides from a diverse selection of car models. The company also collaborates with more than 25 online travel agencies, including major players like Booking.com and Expedia, to enhance its service offerings. By focusing on customer support and ease of use, SmartRyde aims to make travel more comfortable and efficient for its users.

SmartRyde is a Tokyo-based company founded in 2017 that specializes in airport transfer services. It operates a reservation platform that connects travelers with a wide variety of transportation options from over 650 operators worldwide. SmartRyde’s platform is designed to facilitate safe and seamless airport transfers, allowing users to pre-book their rides from a diverse selection of car models. The company also collaborates with more than 25 online travel agencies, including major players like Booking.com and Expedia, to enhance its service offerings. By focusing on customer support and ease of use, SmartRyde aims to make travel more comfortable and efficient for its users.

Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.

Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.